
Personalized Cancer Vaccine Cuts Melanoma Relapse Risk by 42 Percent in Landmark Trial
Doctors are eyeing lung and pancreatic cancer next for an approach in which an mRNA vaccine is developed from the patient’s own cancer.
By HOLLIE McKAY
||National











